EU Committee Nod For Lilly's Ixekizumab In Psoriasis

Product, to be branded as Taltz, looks set to be approved for moderate to severe plaque psoriasis after review by Europe's CHMP, with a US decision date coming up shortly for the Cosentyx competitor.